Kazia director granted 75,000 stock options

Kazia Therapeutics Ltd director Robert F. Apple received a grant of stock options over 75,000 ADSs on January 8, 2026.

Rhea-AI Filing Summary

Kazia Therapeutics Ltd director Robert F. Apple received a grant of stock options over 75,000 ADSs on January 8, 2026. The options have an exercise price of $6.78 per ADS, were granted for no cash consideration, and vest on January 8, 2027. They expire on January 8, 2029, and represent his full reported option holdings from this award.

Insider Trade Summary

Grant/Award: 75,000 shares

Grant/Award 1 txn

Insider APPLE ROBERT F

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	75,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 75,000 contracts (Direct)

Footnotes (1)

1. F1. Represents a board-approved award of 75,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029.

Key Figures

Option grant size: 75,000 options Exercise price: $6.78 per ADS Holdings after grant: 75,000 derivative securities +3 more

6 metrics

Option grant size 75,000 options Employee stock option award over ADSs to director

Exercise price $6.78 per ADS Set by reference to Nasdaq closing price on January 8, 2026

Holdings after grant 75,000 derivative securities Total stock options reported following this transaction

Grant date January 8, 2026 Board-approved option award date

Vesting date January 8, 2027 Date when options become exercisable

Expiration date January 8, 2029 Date when options expire if unexercised

Key Terms

Employee Stock Option, ADSs, Remuneration Committee, exercise price

4 terms

Employee Stock Option financial

"security_title: "Employee Stock Option (right to buy)""

An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.

ADSs financial

"underlying_security_title: "ADSs" and options over ADSs"

Remuneration Committee financial

"approved by the Remuneration Committee on January 8, 2026"

A remuneration committee is a group of independent board members who design, approve and oversee pay packages for a company’s executives and directors. Think of them as the household budget planners for top management: they decide salaries, bonuses and stock awards so pay rewards performance and limits excessive risk. For investors, their role matters because compensation policies affect management incentives, business strategy and the long‑term value shareholders receive.

exercise price financial

"at an exercise price of $6.78 per ADS"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Kazia Therapeutics (KZIA) report for Robert F. Apple?

Kazia Therapeutics reported that director Robert F. Apple received an award of 75,000 stock options over ADSs. The grant is compensation-related, not an open-market purchase or sale, and was approved by the board’s Remuneration Committee on January 8, 2026.

What is the exercise price of Robert F. Apple’s new Kazia (KZIA) stock options?

The stock options granted to Robert F. Apple have an exercise price of $6.78 per ADS. This price was set by reference to the closing price of Kazia’s ADSs on Nasdaq on January 8, 2026, aligning the award with the market level that day.

How many Kazia Therapeutics (KZIA) ADSs are covered by Robert F. Apple’s option grant?

The award covers options over 75,000 Kazia Therapeutics ADSs. Following this grant, the filing shows 75,000 derivative securities held, all tied to this single employee stock option award reported as directly owned by the director.

When do Robert F. Apple’s Kazia (KZIA) stock options vest and expire?

The options granted to Robert F. Apple vest on January 8, 2027, one year after approval. They expire on January 8, 2029, providing a two-year exercise window after vesting for the director to decide whether to exercise the award.

Did Robert F. Apple pay consideration for his Kazia Therapeutics (KZIA) option grant?

No, the filing states the options were granted for no consideration. This means the director did not pay cash to receive the 75,000-option award; any cost arises only if he later exercises at the $6.78 per ADS exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/08/2026 - 04:57 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

APPLE ROBERT F

(Last) (First) (Middle)

THREE INTERNATIONAL TOWERS, LEVEL 24

300 BARANGAROO AVENUE

(Street)

SYDNEY, NSW 2000

(City) (State) (Zip)

AUSTRALIA

(Country)

2. Issuer Name and Ticker or Trading Symbol
KAZIA THERAPEUTICS LTD [ KZIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$6.78	01/08/2026		A		75,000(1)		(1)	(1)	ADSs	75,000	$0	75,000	D

Explanation of Responses:

1. Represents a board-approved award of 75,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029.

	/s/ Jeffrey Bonacorda - Attorney-in-Fact	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)